Clinical observation on change of immunological function after chemotherapy in combination with ubenimex for malignant tumors

Objective: To explore the effect of chemotherapy in combination with ubenimex on immunological function of patients with malignant tumors. Methods: The changes of counts of T-lymphocyte subsets and NK (natural killer) cells in peripheral blood of patients with malignant tumors after chemotherapy alone (n = 150) or in combination with ubenimex (n = 150) were examined by FCM (flow metry). Results: The proportions of CD3+ and CD4+ T-lymphocyte subsets, NK cells (CD3–/CD16+ CD56 +) and the ratio of CD4+/CD8+ in peripheral blood of patients with malignant tumors after chemotherapy in combination with ubenimex were significantly higher than those of patients receiving chemotherapy alone (P < 0.05). The proportion of CD8+ T-lymphocytes was obviously lower in patients receiving chemotherapy in combination with ubenimex than that in patients receiving chemotherapy alone (P < 0.05). Conclusion: Use of ubenimex may improve the immunological function of patients with malignant tumors after chemotherapy. DOI:10.3781/j.issn.1000-7431.2013.04.016